title: [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 4)--Report on clinical usefulness in diagnosis of cerebrovascular diseases].
abstract: Single photon emission computed tomography (SPECT) using 123I-Iomanzenil (IMZ), a tracer which binds specifically to central-type benzodiazepine receptors, was performed in patients with cerebrovascular diseases (CVD) to determine the clinical signicigance of IMZ SPECT studies in evaluating the pathophysiology of CVD. IMZ SPECT images obtained three hours after administration of the tracer were compared with the images of cerebral blood flow (CBF) studies in 206 cases. In regions with decreased CBF, the uptake of IMZ was relatively preserved in patients with cerebral thrombosis in comparison with cerebral embolism, and in those with perforator branch infarction in comparison with cortical infarction. The uptake of IMZ decreased as a function of both the severity of the decrease in the CBF and the duration of illness in regions with a significantly decreased perfusion reserve. These results suggest that decreased IMZ binding in ischemic stroke reflects the neuronal damage caused by the cerebral ischemia. On the other hand, in patients with intracerebral hemorrhage, the cortical uptake of IMZ was relatively well-preserved in regions with decreased CBF, and the decrease in the uptake of IMZ was more profound as a function of the decrease in the CBF, especially in cases of putaminal hemorrhage. These results also suggest that the decreased cortical CBF is a remote effect caused by a neuronal disconnection, and neuronal damage may occur in regions with severely impaired CBF.
authors.affiliation: Fukui Medical School.
authors.forename: K
authors.initials: K
authors.lastname: Torizuka
authors.forename: K
authors.initials: K
authors.lastname: Uemura
authors.forename: M
authors.initials: M
authors.lastname: Toru
authors.forename: Y
authors.initials: Y
authors.lastname: Shinohara
authors.forename: T
authors.initials: T
authors.lastname: Nishimura
authors.forename: Y
authors.initials: Y
authors.lastname: Yonekura
authors.forename: J
authors.initials: J
authors.lastname: Nakagawara
authors.forename: H
authors.initials: H
authors.lastname: Matsuda
authors.forename: F
authors.initials: F
authors.lastname: Sakai
authors.forename: K
authors.initials: K
authors.lastname: Matsuda
authors.forename: H
authors.initials: H
authors.lastname: Fukuyama
authors.forename: K
authors.initials: K
authors.lastname: Morimoto
mesh_terms: D001921:Brain / Q000000981:diagnostic imaging*; D002561:Cerebrovascular Disorders / Q000000981:diagnostic imaging*; D005442:Flumazenil / Q000031:analogs & derivatives*; D058785:GABA-A Receptor Agonists; D006801:Humans; D007457:Iodine Radioisotopes; D007564:Japan; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D058785:GABA-A Receptor Agonists; D007457:Iodine Radioisotopes; D005442:Flumazenil; C063038:iomazenil